🤯 Have you seen our AI stock pickers’ 2024 results? 84.62%! Grab November’s list now.Pick Stocks with AI

Agios Pharm (AGIO)

NASDAQ
Currency in USD
44.87
+0.44(+0.99%)
Closed
After Hours
46.10+1.23(+2.74%)
AGIO Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
43.3245.26
52 wk Range
20.4053.29
Prev. Close
44.43
Open
44.93
Day's Range
43.32-45.26
52 wk Range
20.4-53.29
Volume
672,853
Average Volume (3m)
466,297
1-Year Change
99.51%
Book Value / Share
Unlock
Fair Value
Unlock
Fair Value Upside
Unlock
AGIO Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
53.62
Upside
+19.50%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year
Show more

InvestingPro Research for Agios Pharm


Navigating Turbulence
Agios faces challenges in the sickle cell disease market while pursuing opportunities in thalassemia and myelodysplastic syndromes, shaping its strategic direction.
Financial Fortitude
With a robust $1.7 billion cash position, Agios stands ready to fund pipeline development and explore strategic opportunities in the biopharma landscape.
Pipeline Potential
Explore Agios' diverse portfolio, including Pyrukynd's label expansion and emerging therapies, poised to drive future growth in genetic diseases and oncology.
Market Dynamics
Analyst targets range from $55 to $56, reflecting cautious optimism amidst regulatory uncertainties and potential market share gains in sickle cell disease.
Read full SWOT analysis

Agios Pharm Company Profile

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Compare AGIO to Peers and Sector

Metrics to compare
AGIO
Peers
Sector
Relationship
P/E Ratio
3.8x−1.4x−0.6x
PEG Ratio
0.01−0.010.00
Price/Book
1.6x2.5x2.6x
Price / LTM Sales
77.8x10.9x3.2x
Upside (Analyst Target)
23.7%227.9%48.6%
Fair Value Upside
Unlock13.3%7.0%Unlock

FAQ

What Is the Agios Pharm (AGIO) Stock Price Today?

The Agios Pharm stock price today is 44.87

What Stock Exchange Does Agios Pharm Trade On?

Agios Pharm is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Agios Pharm?

The stock symbol for Agios Pharm is "AGIO."

What Is the Agios Pharm Market Cap?

As of today, Agios Pharm market cap is 2.56B.

What is Agios Pharm Earnings Per Share?

The Agios Pharm EPS is 11.93.

What Is the Next Agios Pharm Earnings Date?

Agios Pharm will release its next earnings report on 12 Feb 2025.

From a Technical Analysis Perspective, Is AGIO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.